Pharmaceutical organizations spend between 4-12% of their annual revenue on patient support services (PSPs) and between $3M-$30M on patient co-pay buy down. For emerging biopharma (EBP), the upfront investment and the opportunity cost relative to perceived other commercial priorities often forces trade-offs on program design.
Please join our panelists as we discuss:
Susan Kitlas
Vice President, Pre-Commercial Sales, IQVIA
Adam Sohn
Vice President, Patient Engagement and New Commercial Model Digital, IQVIA
Kristina Jones
Principal, Patient Engagement, IQVIA
Jennifer Millard
Vice President, Patient Support Services, IQVIA